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Summary 
Background. The most common complication of microsurgical reconstruction is graft 
failure secondary to thrombosis. It is clear that thromboprophylaxis is helpful for a 
successful microsurgery. However, it’s also obvious that thrombosis can’t be avoided 
in cases of poor microsurgical technique. There is no consensus regarding the use of 
anticoagulation therapy during and after microsurgery. The authors compared two dif-
ferent antithrombotic prophylaxis protocols used in the past ten years, and analyzed 
the effectiveness and risks of different pharmacological protocols. 
Materials and methods. The authors performed a retrospective review of microsur-
gical patients operated between 2005-2014 by the same surgical team. 37 patients 
(Group A) operated between 2005-2010 and 45 patients (Group B) operated between 
2011-2014 were selected. The majority of patients had generic and specific risk fac-
tors. Different thromboprophylaxis therapies were used in the two groups. While re-
viewing medical records, the authors compared Hb values before and after surgery, 
the free flap success rate, the need for blood transfusions intra and post-op in order to 
assess the efficacy (failure rate), and safety of the administered antithrombotic thera-
pies (bleeding complications). 
Results. The pharmacological protocol used for the patients from Group B was more 
effective and less risky compared to results obtained from Group A. The therapy used 
in Group B did not increase the risk of bleeding and postoperative blood loss, and the 
flap success rate in Group B was significantly higher than that of Group A  (p<0.000). 
Discussion and Conclusion. This study suggests that even in a perfect microanasto-
mosis, prothrombotic mechanisms are activated, which lead to flap failure. A reasoned 
and balanced drug therapy can counteract the natural tendency of pedicle thrombosis, 
without exposing the patient to bleeding complications. Vasoactive drugs, although 
still experimental in microsurgery, may be used in the near future in order to further 
improve the success rates of free flaps. 
Introduction 
The most common complication of microsurgical reconstruction is graft failure secon-
dary to arterial or venous thrombosis.  
Dissecting the pedicle, preparing the vessels and passing the needle through the wall 
all involve a lesion of the intimal layer 
with exposure of sub-endothelial layer, 
even in technically perfect microanasto-
moses. 
Persistence of the thread within the vas-
cular  lumen  and  turbulent  trans-
anastomotic blood flow activate hemo-
stasis, platelets aggregate and a white 
clot forms. This process alone can induce 
endovascular thrombosis.   
Blood stasis at the anastomotic site acti-
vates the coagulation system.  
Surgery (vessels kinking, compression by 
hematoma  or  edema)  and/or  medical 
condition (oncologic or infection disease, 
hypovolemia, hyponatremia) can cause 
blood stasis followed by arterial and ve-
nous thrombosis. [1-5] 
Therefore, it is clear that thrombopro-
phylaxis is helpful for a successful micro-
surgery.  However  it  will  not  prevent 
thrombosis in case of poor microsurgical 
technique.  
The reason for using antithrombotic pro-
phylaxis is to act on a technically perfect 
microanastomosis, using drugs that se-
lectively work with different mechanisms 
of  action,  and  on  different  tar-
gets.  Drugs can be administered for the 
following reasons: 
- Avoid stasis. 
- Increase the perfusion pressure.  
- Reduce hyperviscosity, using a moder-
ate normovolemic hemodilution and he-
matocrit correction.  
- Reduce hypercoagulability, acting both 
on the primary and secondary hemosta-
sis (platelets and the coagulation cas-
cade). 
The use  of  systemic  vasoactive drugs 
(such as papaverine, lidocaine or prosta-
cyclin) is still in the experimental stage. 
However, they have a limited use for the 
local irrigation of the anastomosis or in 
experimental conditions. 
The use of streptokinase and urokinase is 
limited to rescue procedures for intra- or 
perioperative  vascular  thrombosis,  not 
for prophylaxis because of the high risk 
of bleeding [6].  
The three main pharmacological agents 
that had been used for thromboprophy-
laxis in  microsurgery:  aspirin, heparin 
and dextran. [5,8] 
Therapeutic protocols suggest the combi-
nation of more drugs in order to reduce 
platelet aggregation and the activation of 
the  coagulation  cascade  (aspirin  and 
heparin), maintaining a constant  blood 
flow and perfusion pressure during and 
after  surgery  (fluid  therapy,  steroids, 
dextran), and decreasing blood viscosity 
by reducing the hematocrit (isovolemic 
hemodilution).  Nowadays,  the  use  of 
dextran is no longer indicated because 
the benefits do not outweigh the risks 
(anaphylaxis,  pulmonary  and  cerebral 
edema) [5-10]. 
The  ideal  antithrombotic  agent  should 
have an effective anticoagulation activity 
to successfully prevent pedicle thrombo-
sis, minimal side effects, low complica-
tions rates related to perioperative and 
postoperative bleeding, and be easy to 
administer.  
We compared our experience with two 
different  perioperative  protocols  of 
thromboprophylaxis and we analyzed the 
reasons that led us to modify our throm-
boembolic prophylaxis protocol. 
 
Materials and Methods 
The authors performed a retrospective 
review of medical records of patients that 
had microsurgical reconstruction between 
2005 and 2014. Only the patients who 
received prophylactic antithrombotic drug 
therapy were selected. 
The majority of patients had generic and 
specific risk factors. 
The clinically relevant risk factors were:  
high body mass index (BMI), diabetes, 
smoking,  alcohol  use,  ASA  III-IV 
(according to American Society of Anes-
thesiologists  classification),  associated 
diseases (cardiac, metabolic, neurologi-
cal, infections, tumors), medical history 
of  the  neoadjuvant  chemotherapy  and 
radiotherapy. 
For these patients the evaluated factors 
were postoperative hemoglobin, postop-
erative blood transfusions, the microsur-
gical flap failure rate, regardless of the 
type of flap (diep, alt, vastus lateralis, 
serratus, latissimus dorsi, forearm flap, 
etc.), of the anatomical region involved 
(head and neck, breast, lower or upper 
limbs), and the presence of comorbid-
ities. It was not technically possible to 
make  an  assessment  of  blood  loss 
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through  drainage  or  dressing  because 
the data was not always reported in the 
medical record, or was not reliable for all 
patients.  In  both  groups,  the  post-
operative blood loss was assessed com-
paring the values of pre-operative and 
post-operative Hb (24h after surgery). 
The antithrombotic drug protocol used 
between 2011 and 2014 was different 
from the one used between 2005 and 
2010: 
A total of 42 patients in the period be-
tween 2005 and 2010 that underwent a 
microsurgery had a specific antithrom-
botic drug protocol. Five of the 42 pa-
tients  were excluded from the  group 
because they received, in addition to the 
antithrombotic drug therapy, a preopera-
tive normovolemic hemodilution by self-
bloodletting. This procedure, which was 
initially part  of  the implemented anti-
thrombotic protocol, could only be ap-
plied to few of the selected patients. On-
cological patients or patients with com-
plex drugs therapy were excluded, con-
sequently the 5 patients that  received 
self-bloodletting were excluded from this 
study. 
Group A: A total of 37 patients (Group 
A) were selected. 23 males and 14 fe-
males in  which  the  prophylactic  anti-
thrombotic therapy used was:  
- 12 hours before surgery: Intravenous 
infusion  of  high-dose  aspirin  (500  mg 
IV),  methylprednisolone  500  mg,  and 
pantoprazole 40 mg in 500 cc of saline. 
- Before releasing the clamps: Intrave-
nous  bolus  of  unfractionated  Heparin 
(UFH, 5000 U)  
- Post-operation: A standard fluid ther-
apy (1.5-2 liters) was administered for 
24 hours (or more, up to recovery of oral 
ingestion), also  ASA 500  mg,  methyl-
prednisolone 500 mg, and pantoprazole 
40  mg intravenously  every  24h  for  3 
days post-op. 
- Antibiotic prophylaxis with amoxicillin 
and  clavulanic  acid  or  cefazolin 
(depending  on  the  anatomical  site 
treated) [11-12]  
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Figure 1. Pre-operative and post-operative hemoglobin values in Group A and B. 
There was no statistically significant difference between pre-operative hemoglobin 
values for the two groups (p>0.7).  
The samples were therefore considered homogeneous and comparable.  
- 24 hours after surgery: subcutaneous 
injection of LMWH (dosage necessary for 
the prevention of  DVT was calculated 
based on patient body weight), adminis-
tered daily for 20 days; 
Group B:  A total of 45 patients, 28 
males and 17 females that underwent 
microsurgery between 2011 and 2014, 
had a specific antithrombotic drug proto-
col: 
- 48 hours before surgery: ASA 100 mg 
(Cardioaspirin) orally (1 per day); 
- 12 h before surgery: slow I.V. 500 cc 
Infusion of saline with pantoprazole 40 
mg and methylprednisolone 500mg; 
- During surgery:  100 mg of ASA I.V. 
with fluid therapy support. (Ht control, 
never less than 30%); 
-  Before  microsurgical  step:   intra-
arterial  and intravenous irrigation with 
heparin (LMWH), intra-arterial irrigation 
with prostacyclin and lidocaine. 
Post-op:    
-Subcutaneous  injection  of  LMWH 
(dosage necessary for the prevention of 
DVT was  calculated based on  patient 
body weight) once a day for 30 days; 
- Fluid therapy (1.5-2L, up to recovery of 
oral ingestion) and I.V. methylpredniso-
lone 500mg + 100mg ASA + pantopra-
zole 40mg, after 24 hours for 3 days; 
- 100 mg ASA orally, 1per day for 4 ad-
ditional days.  
Two patients from each group were ex-
cluded (total of 4 patients) because they 
had  received  blood  transfusions  or 
plasma expanders during or within 24 h 
after surgery.  
Clinical data for the two selected groups 
was compared (see Figure1). 
All diabetic patients that were adminis-
tered methylprednisolone required care-
ful  monitoring  of  blood glucose  levels 
and insulin treatment. 
 
Statistical Analysis  
For  continuous  variables,  the  mean, 
standard deviation, minimum and maxi-
mum were calculated. 
For  categorical  variables,  the  corre-
sponding percentages were calculated. 
Considering the sample size, the Mann-
Whitney nonparametric test was used. 
SPSS (IBM, New York) ver.20.0 was used 
for statistical analysis  
Results 
Pre-operative and post-operative hemo-
globin, post-operative blood transfusions, 
and the failure rate of microsurgical flap 
were evaluated in the two groups of pa-
tients. Other parameters, such as blood 
loss in  surgical  drains,  the  anatomical 
site, and the type of flap, were not con-
sidered, because the data was not readily 
available or comparable. (Figure 1) 
There was no statistically significant dif-
ference between pre-operative hemoglo-
bin values for the two groups (p>0.7). 
The samples were therefore considered 
homogeneous and comparable. 
Post-operative blood loss was assessed in 
both groups comparing pre-operative and 
post-operative hemoglobin (24 hours af-
ter  surgery).  The mean  blood loss in 
Group A was 4.67 mg/dl of hemoglobin. 
Thirty five percent of these patients re-
ceived at least one blood transfusion post
-operatively and there was a 16% micro-
surgical flap failure. In Group B the mean 
blood loss 24 hours after surgery was 
3.52 mg/dl of hemoglobin, and 22% of 
the patients who received a blood trans-
fusion postoperatively had a 13.3% flap 
failure. 
Blood loss in Group A was significantly 
greater than Group B (p<0,01).  
This supports the hypothesis that drug 
therapy used in Group B did not increase 
the risk of  bleeding and postoperative 
blood loss. 
Moreover, the flap success rate in Group 
B was significantly higher than the re-
sults from Group A (p<0.000), suggest-
ing that the antithrombotic therapy used 
in Group B was more effective. 
The greater blood loss and flap failure in 
Group A may reflect various complica-
tions, including hematoma of the pedicle, 
vasospasm secondary to anemia, and 
infections secondary to hematoma and 
transfusion.  
 
Discussion 
A reasoned and balanced pharmacologi-
cal  thromboprophylaxis  can  counteract 
the natural tendency of pedicle thrombo-
sis of  microsurgical flaps, especially in 
patients with risk factors.  
Our protocol has evolved. 
As previously mentioned, our pharmacol-
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ogical  protocol  has  changed in  recent 
years. Pre-operative autologous transfu-
sion has been eliminated and replaced by 
pre-operative  moderate  hemodilution. 
Dosage and timing of drug administra-
tion have also been modified. 
Initially the authors adopted a promising 
protocol of normovolemic hemodilution. 
Two weeks prior to surgery, patients un-
derwent phlebotomy and simultaneous 
infusion of a corresponding amount of 
saline  solution  (removal  of  300  cc  of 
blood and infusion of 300 ml of saline). 
This procedure had several advantages: 
1) If necessary, during or after surgery, 
the patient was transfused his own blood 
(reduction of heterologous transfusions). 
2) Normovolemic hemodilution, with re-
duction in blood viscosity. 
3) Phlebotomy stimulated the bone mar-
row, resulting in increased reticulocyte 
counts, which is advantageous during the 
postoperative period. 
Although potentially useful, pre-operative 
phlebotomy is labor intensive and could 
not be applied to all patients (for exam-
ple patients with comorbid diseases or 
multi drug therapy, cancer patients etc.). 
For this reason it was quickly abandoned 
and replaced with normovolemic hemodi-
lution administering 500cc of saline in-
travenous the evening before surgery. 
Normovolemic hemodilution is a standard 
procedure in microsurgery aimed at re-
ducing blood viscosity. 
Normovolemic  or  isovolemic  hemodilu-
tion [13-15] improves blood flow by re-
ducing viscosity and platelet aggregation, 
and increases the number of unblocked 
capillaries. The optimal hematocrit value 
should be 30. However, patients without 
complications,  also  tolerate  hematocrit 
values between 25 and 30. Further re-
ductions in hematocrit did not result in 
greater benefits. In fact, any benefit may 
be  overcome by  the  decrease  in  O2-
carrying capacity. A low hematocrit value 
also increases cardiac work (important in 
patients with low cardiac reserve). 30% 
Ht offers the best balance between vis-
cosity and O2-carrying capacity. 
Thirty five percent of patients (13 out of 
37) who underwent microsurgical recon-
struction  with  prophylactic  antithrom-
botic therapy between 2005 and 2010 
(Group A)  were  transfused postopera-
tively due to anemia. This prompted the 
authors  to  revise  the  pharmacological 
therapy in order to minimize side effects 
without lowering the success rate of the 
microsurgical procedure. The flap failure 
rate in Group A was 16% (6 of 37 pa-
tients). The intravenous bolus of unfrac-
tionated Heparin was no longer adminis-
tered before releasing the flap, because 
of high blood loss postoperatively. This 
was replaced with a subcutaneous injec-
tion of LMWH, starting the day after sur-
gery (administered once per day for 20 
days). For the same reason, aspirin, ini-
tially administered in high doses (500 mg 
IV  pre-operative  and  post-operative, 
every day for 5 days), was administered 
in low doses (100 mg Cardioaspirin) at 
least one day prior to surgery. 
The  pharmacological  protocol  currently 
used by the authors is described in Table 
1. 
The rationale of the Protocol is: 
Pre-, intra- and post-operative hemodilu-
tion (with HT 30) reduces blood viscosity, 
induces  peripheral  vasodilatation  with 
improved perfusion of the microcircula-
tion, and improves cardiovascular per-
formance.  
One of the innovations is to use an intra-
venous  infusion of  methylprednisolone. 
This is not described in the literature as a 
drug commonly used for antithrombotic 
prophylaxis in microsurgery. Methylpred-
nisolone improves microcirculation; it has 
a protective action on the vessels, inhib-
iting phospholipase A2 (an enzyme in-
volved in the metabolism of phospholip-
ids, which leads to the formation of ara-
chidonic  acid,  the  substrate  on  which 
COX acts for the formation of thrombox-
ane A2), improving the hypercoagulable 
state  during  the  perioperative  period 
through the  reduction of  inflammatory 
cytokines. Additionally, it increases and 
supports the systemic blood pressure. In 
fact, a reduction of systemic blood pres-
sure during or after surgery is crucial be-
cause it induces peripheral vasoconstric-
tion via catecholamine-mediated mecha-
nisms, which are difficult to overcome. 
The Low-dose ASA reduces platelet ag-
gregation by electively inhibiting the pro-
duction of TXA2 without interfering with 
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the production of prostacyclin. The effect 
of ASA lasts the lifetime of platelets (8-
10 days), and it is the reason why ad-
ministering  low  doses  (100mg)  48-24 
hours prior to the surgical procedure is 
sufficient. The  ideal  dose  is  100  mg, 
orally or intravenously, per day for 7 
days, and has little side effects. [17-19] 
The subcutaneous injection of Low Mo-
lecular  Weight  Heparin  after  surgery 
should be administrated for prophylaxis 
of DVT, and this prevention therapy also 
affects the patency of the microanasto-
moses. Similarly to Unfractionated Hepa-
rin,  intraluminal  irrigation  with  LWMH 
increases the vessel patency, with mini-
mal systemic side effects. LMWH is safer, 
in terms of hemorrhagic risk, than UFH 
and it is considerably easier to adminis-
ter. [19-21] 
Local intraluminal irrigation of the pedi-
cle, before a microsurgical suture, is al-
ways done with LMWH and lidocaine. The 
use of urokinase or streptokinase is lim-
ited to the treatment of thrombosis in 
the immediate postoperative period, and 
never  for  antithrombotic  prophylaxis. 
[22] 
The use of vasoactive drugs systemically, 
such as prostacyclin, which is a powerful 
vasodilator, is still  in the experimental 
stage on animal models. The systemic 
hypotensive effect of these drugs limits 
their  use  in  a  clinical  setting  because 
they may impair microcirculation in the 
free flap. There are some positive results 
from the local application (irrigation) of 
the drug within the lumen of the vessels, 
but further studies are required.  
Intraluminal administration of prostacy-
clin before the vascular anastomosis in-
duces a visible and lasting vasodilation 
(under the microscope) of  the arterial 
flap, which becomes perfectly round and 
dilated. This technically facilitates micro-
anastomosis. However, it is difficult to 
prove and quantify the extent of vessel 
dilatation.  
The irrigation of the artery with prostacy-
clin does not replace irrigation with hepa-
rin, which should always be carried out 
immediately after disconnecting the flap 
from the donor site. Further studies are 
needed to demonstrate the vasodilating 
effect of the drug on the vessels of the 
pedicle. [23-26] 
The pharmacological  protocol  does not 
increase  the  risk  of  intra  and  post-
operative  bleeding, and seems to im-
prove the vascular patency and the per-
fusion of free flaps.  
The low post-operative blood loss and the 
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Table 1. The pharmacological protocol currently used by the authors. 
Timing Drug 
48 h before surgery ASA, 100 mg per day, orally 
12h before surgery 
NaCl 0.9% + pantoprazole 40mg 
+ methylprednisolone 500 mg I.V. 
During surgery ASA, 100mg I.V. 
Before microsurgical time 
Intravenous irrigation of heparin 
Intrarterial irrigation of prostacyclin 
Post-operative 
Subcutaneous injection of LMWH, 1 per day, 
Fluid therapy (1.5-2 liters up to recovery of oral 
alimentation)+500mg methylprednisolone 
+ 40 mg pantoprazole in 24 hours for 3 days. 
100 mg ASA, orally, 1 per day for 4 days more. 
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absence of hematoma at the site of the 
anastomosis confirm the safety of  the 
drug protocol  employed. The free flap 
success rate is significantly increased in 
Group B. The vital signs, blood counts 
and APTT were almost normal. There was 
no change in drug-induced coagulation. 
No cases of complications related to drug 
therapy (such as HIT) were observed.  
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